CPT code 0207U identifies the Discern™ Proprietary Laboratory Analyses (PLA) test by NeuroDiagnostics, a specialized laboratory assay that quantitatively images phosphorylated ERK1 and ERK2 in cultured skin specimens to support identification of Alzheimer disease. As a PLA code, 0207U is unique to a single manufacturer's test and is reportable only in conjunction with CPT code 0206U. Nationally, PLA codes like 0207U are significant because they capture emerging, proprietary diagnostic technologies that can influence clinical pathways for neurodegenerative disease diagnosis and affect laboratory billing and coverage reviews.

Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise description of the test and its clinical context, an overview of payer coverage considerations, and reference points for common billing practice. The publication also outlines typical sites of service and the service type to clarify coding and billing settings.

This summary provides clinicians, laboratory managers, and billing professionals with essential context about CPT code 0207U: what the code represents, its clinical purpose in Alzheimer disease identification, and the national payer landscape relevant to proprietary laboratory diagnostics. Data not available in the input is noted where applicable.